Celularity – a biotechnology company developing allogeneic cell therapies and biomaterial products – recently announced a multi-year Research Collaboration Services Agreement with Regeneron Pharmaceuticals to support the research of Regeneron’s allogeneic cell therapy candidates.
The agreement’s initial focus is the research on a targeted allogeneic gamma delta chimeric antigen receptor (CAR) T-cell therapy owned by Regeneron designed to enhance proliferation and potency against solid tumors. And the research will take place at Celularity’s state-of-the-art facility located in Florham Park, N.J. The financial terms were not disclosed.
KEY QUOTE:
“The agreement with Regeneron announced today is an important milestone for Celularity that recognizes our expertise in the research of cellular therapies, including the engineering of CAR-T cells. We believe that this relationship paves the way for future industry collaborations leveraging our world class cell therapy facilities and capabilities. We have long admired the exceptional scientific legacy at Regeneron and welcome the opportunity to collaborate with a world leader in innovative medicines.”
— Robert J. Hariri, M.D., Ph.D., Celularity’s CEO, Chairman and Founder
